DR. ANDREW A. WOLFF, M.D.
Osteopathic Medicine in San Francisco, CA
License number
California G054236
Category
Osteopathic Medicine
Type
Cardiovascular Disease
Address
Address
4150 Clement St Department Of Veterans Affairs Medical Ctr, San Francisco, CA 94121
Phone
(415) 221-4810
(415) 608-3431
(415) 608-3431
Personal information
See more information about ANDREW A. WOLFF at radaris.comName
Address
Phone
78 Chancellor Pl, Berkeley, CA 94705
1375 Montecito Ave APT 29, Mountain View, CA 94043
130 Paseo De La Concha, Redondo Beach, CA 90277
214 S Carondelet St, Los Angeles, CA 90057
2140 Taylor St APT 803, San Francisco, CA 94133
Organization information
See more information about ANDREW A. WOLFF at bizstanding.comAndrew Wolff MD
4150 Clement St, San Francisco, CA 94121
Industry:
Internist
Phone:
(415) 221-4810 (Phone)
Andrew Aloysius Wolff
Professional information
See more information about ANDREW A. WOLFF at trustoria.com
Chief Medical Officer, Senior Vice President, Clinical Research And Development At Cytokinetics, Inc.
Chief Medical Officer, Senior Vice President, Clinical Research And Development At Cytokinetics, Inc.
Position:
Chief Medical Officer, Senior Vice President, Clinical Research and Development at Cytokinetics, Inc.
Location:
San Francisco Bay Area
Industry:
Biotechnology
Work:
Cytokinetics, Inc.
since Sep 2004
-
Chief Medical Officer, Senior Vice President, Clinical Research and Development
CV Therapeutics
1994 - 2004
-
Chief Medical Officer, Senior Vice President, Clinical Research and Development
Syntex
1988 - 1994
-
Executive Director & Clinical Program Leader, New Molecules
Skills:
Clinical Research, Biotechnology, Clinical Development, Clinical Trials, Oncology, Pharmaceutical Industry, Lifesciences, CRO, FDA, Regulatory Submissions, Pharmacology, Regulatory Affairs, Cardiology, R&D, Drug Discovery, Drug Development
Partial Fatty Acid Oxidation Inhibitors In The Treatment Of Congestive Heart Failure
Partial Fatty Acid Oxidation Inhibitors In The Treatment Of Congestive Heart Failure
US Patent:
6677342, Jan 13, 2004
Filed:
Aug 27, 2002
Appl. No.:
10/228573
Inventors:
Andrew A. Wolff - San Francisco CA
Brent Blackburn - Los Altos CA
Hani Naief Sabbah - Waterford MI
William Clark Stanley - Shaker Heights OH
Brent Blackburn - Los Altos CA
Hani Naief Sabbah - Waterford MI
William Clark Stanley - Shaker Heights OH
Assignee:
CV Therapeutics, Inc. - Palo Alto CA
International Classification:
A61K 31495
US Classification:
51425212
Abstract:
Methods are disclosed for treating congestive heart failure with partial inhibitors of fatty acid oxidation. The compounds increase cardiac performance without affecting heart rate, blood pressure, or oxygen consumption.
Andrew Aloysius Wolff, San Francisco CA
Andrew Aloysius Wolff, San Francisco CA
Specialties:
Internal Medicine, Cardiovascular Disease, Cardiology
Work:
San Francisco Veterans Affairs Medical Center
4150 Clement St, San Francisco, CA 94121
4150 Clement St, San Francisco, CA 94121
Education:
Washington University at St. Louis (1980)
Owner, Law Office Of Andrew Wolff
Owner, Law Office Of Andrew Wolff
Position:
Owner at Law Office of Andrew Wolff
Location:
San Francisco Bay Area
Industry:
Law Practice
Work:
Law Office of Andrew Wolff
-
Owner
Education:
University of California, Santa Cruz
Sustained Release Ranolazine Formulations
Sustained Release Ranolazine Formulations
US Patent:
6620814, Sep 16, 2003
Filed:
Sep 27, 2002
Appl. No.:
10/256993
Inventors:
Andrew A. Wolff - San Francisco CA
Fiona Baker - Dumfermline, GB
John Langridge - Wrexham, GB
Fiona Baker - Dumfermline, GB
John Langridge - Wrexham, GB
Assignee:
CV Therapeutics, Inc. - Palo Alto CA
International Classification:
A61K 31495
US Classification:
51425217, 424465
Abstract:
A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4. 5 and soluble in aqueous media above pH 4. 5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
Sustained Release Ranolazine Formulations
Sustained Release Ranolazine Formulations
US Patent:
6369062, Apr 9, 2002
Filed:
Mar 29, 2000
Appl. No.:
09/538337
Inventors:
Andrew A. Wolff - San Francisco CA
Fiona Baker - Dunfermline, GB
John Langridge - Wrexham, GB
Fiona Baker - Dunfermline, GB
John Langridge - Wrexham, GB
Assignee:
CV Therapeutics, Inc. - Palo Alto CA
Syntex (USA) Inc. - Palo Alto CA
Syntex (USA) Inc. - Palo Alto CA
International Classification:
A61K 3150
US Classification:
51425212, 514964
Abstract:
A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4. 5 and soluble in aqueous media above pH 4. 5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
Use Of Ranolazine For Elevated Brain-Type Natriuretic Peptide
Use Of Ranolazine For Elevated Brain-Type Natriuretic Peptide
US Patent:
2008023, Sep 25, 2008
Filed:
Mar 20, 2008
Appl. No.:
12/052381
Inventors:
Brent Blackburn - Los Altos CA, US
Marcus Jerling - Bromma, SE
Andrew Wolff - San Francisco CA, US
Marcus Jerling - Bromma, SE
Andrew Wolff - San Francisco CA, US
International Classification:
A61K 9/22, A61K 31/495, A61P 9/00
US Classification:
424468, 51425212
Abstract:
This invention is directed to the use of ranolazine to reduce the risk of adverse coronary events in a mammalian patient. Typically, the natriuretic peptide is associated with coronary disease, acute coronary syndrome, and/or diastolic dysfunction. Ranolazine may be administered to the patient as an intravenous solution or in an oral dose.
Sustained Release Ranolazine Formulations
Sustained Release Ranolazine Formulations
US Patent:
2004009, May 20, 2004
Filed:
Jul 7, 2003
Appl. No.:
10/614420
Inventors:
Andrew Wolff - San Francisco CA, US
Fiona Baker - Dunfermline, GB
John Langridge - Llandegla, GB
Fiona Baker - Dunfermline, GB
John Langridge - Llandegla, GB
International Classification:
A61K031/495, A61K009/20
US Classification:
514/252120, 424/465000
Abstract:
A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
Use Of Ranolazine For The Treatment Of Cardiovascular Diseases
Use Of Ranolazine For The Treatment Of Cardiovascular Diseases
US Patent:
2008021, Sep 4, 2008
Filed:
Feb 13, 2008
Appl. No.:
12/030587
Inventors:
Markus Jerling - Bromma, SE
Andrew Wolff - San Francisco CA, US
Andrew Wolff - San Francisco CA, US
International Classification:
A61K 31/495, A61P 3/00, A61P 9/00
US Classification:
51425212
Abstract:
Disclosed are methods for treating patients suffering from cardiovascular diseases comprising administering an intravenous (IV) infusion of ranolazine. In one embodiment, the IV infusion of ranolazine is followed by an orally administered sustained release ranolazine dosage formulation to maintain human ranolazine plasma levels at therapeutic levels in patients.
Method Of Treating Diabetes
Method Of Treating Diabetes
US Patent:
2004006, Apr 1, 2004
Filed:
May 21, 2003
Appl. No.:
10/443314
Inventors:
Andrew Wolff - San Francisco CA, US
Markus Jerling - San Francisco CA, US
Markus Jerling - San Francisco CA, US
International Classification:
A61K031/495, A61K031/496
US Classification:
514/252120, 514/254110
Abstract:
Methods are provided for treating diabetes, lowering plasma level of HbA1c, glucose plasma levels, total cholesterol plasma level, and/or triglyceride plasma level while increasing HDL cholesterol levels and delaying onset of diabetic retinopathy in a diabetic, pre-diabetic, or non-diabetic mammal while minimizing undesirable side effects.